Clinical and Economic Value of Tralokinumab (ADBRY®) for Patients With Moderate to Severe Atopic Dermatitis

This clinical brief is intended for payers, formulary committee members, drug selection panels, and other similar multidisciplinary individuals or entities. It contains health care economic information to aid in the selection of drugs for coverage or reimbursement. It is not intended for health care providers making individual prescribing decisions or for consumers.